Immunocore reaches target enrollment in registrational trial
Immunocore announced it achieved the enrollment goal for the TEBE-AM Phase 3 trial of KIMMTRAK in advanced melanoma. Topline data is expected as early as the end of 2026.
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Immunocore announced it achieved the enrollment goal for the TEBE-AM Phase 3 trial of KIMMTRAK in advanced melanoma. Topline data is expected as early as the end of 2026.
Armata Pharmaceuticals received a Breakthrough Therapy designation from the FDA for AP-SA02 based on Phase 2 clinical data showing potential for substantial improvement over existi…
Corbus reported CRB-913 achieved a mean weight loss of 5% at 60 mg, supporting its potential as a novel oral obesity treatment. The shares are set to open higher following this tri…
Bally's Corp secured $400 million in financing to further develop its new casino and resort in the Bronx. The funding package, led by WhiteHawk Capital Partners, is expected to clo…
Flowserve appointed Brian Ezzell as Senior Vice President and CFO, succeeding Amy Schwetz while maintaining full-year guidance.
Hain Celestial has entered a definitive agreement to sell its businesses, with Aurelius acquiring the company. This transaction will result in the company delisting from NASDAQ. Th…
Brookfield Asset Management and Brookfield Corporation will host their 2026 Investor Days on September 17, 2026, in New York. This provides an update on strategic initiatives and f…
Toyota Motor Credit Corp entered into an amended and restated agency agreement for a 60 billion Euro medium-term note program with its subsidiary and agent, dated September 11, 202…
The company agreed to sell shares of its Common Stock to an investor at a price of $4.80 per share in a private placement transaction.
Perspective Therapeutics and Merck are partnering to evaluate [212Pb]PSV359 combined with Keytruda in solid tumors, potentially reshaping the tumor microenvironment for improved ca…
Lipocine began its BLOOM Phase 3 trial for LPCN 1154 to support a potential 505(b)(2) NDA, utilizing existing resources despite past data anomalies.
WhiteFiber, Inc. filed an 8-K with an investor presentation, explicitly noting it contains forward-looking statements and cautioning about the risks and uncertainties involved. The…
Larry Ellison has cancelled his 10b5-1 stock sales plan, signaling continued confidence. The departure of a CEO's planned sales often signals bullish insider support.
Artificial Intelligence Technology Solutions announced the successful integration of its RAD robotics with the Immix monitoring platform, making its ROSA and RIO technologies ready…
Trump Pushes Back on AI Slowdown, Says 'Whoever Wins With AI Wins,' Microsoft CEO Satya Nadella Says Tech Must Stay 'Under Human Control'
Anthropic Picks Nasdaq for Its $2 Trillion IPO, Tells Investors It Expects a Second Consecutive Profitable Quarter: Reports
Reported Earlier, Johnson & Johnson Says Rybrevant Plus Chemotherapy Cuts Risk Of Death By 43% Versus Chemotherapy Alone When Adjusted For Crossover In Final PAPILLON Overall Survi…
'Anthropic Tells Investors It Will Be Profitable For Second Straight Quarter' - FT
Jim Cramer Calls This Cybersecurity Stock a 'Must Buy' Amid Emerging AI Threats: Here's Why
Patrick Bet-David Warns Monday Could Be a ‘Bloodbath’ for Stocks as AI Safety Debate Rattles Markets: Samsung, SK Hynix, SoftBank Lead Asian Selloff